Novel treatment approaches are required for relapsed small cell lung cancer (SCLC). Previous studies showed promising activity for lurbinectedin combined with topoisomerase inhibitors in preclinical models of other solid tumors.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 03 Mar 2026.
The item focuses on Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
Review the original article for the full source wording and details.